Plasma homocysteine status in patients with ankylosing spondylitis

@article{Wei2006PlasmaHS,
  title={Plasma homocysteine status in patients with ankylosing spondylitis},
  author={James Cheng‐Chung Wei and Ming-Shiou Jan and Chen-Tung Yu and Yi-Chia Huang and Chi-Chiang Yang and Hsi-Kai Tsou and Hong-Shan Lee and Chang-Tei Chou and Gregory Jiazer Tsay and Ming-chih Chou},
  journal={Clinical Rheumatology},
  year={2006},
  volume={26},
  pages={739-742}
}
Homocysteine (Hcy), a sulfur-containing amino acid, is eliminated through B vitamins-dependent pathways. Hyperhomocysteinemia has been found to be an independent risk factor for atherosclerotic cardiovascular, cerebrovascular, and peripheral vascular diseases. Recently, psoriasis, lupus, and rheumatoid arthritis were reported to be associated with hyperhomocysteinemia. This study was aimed to evaluate the changes of plasma Hcy level before and after sulfasalazine and MTX therapy in patients… Expand
Serum homocysteine level in patients with ankylosing spondylitis
TLDR
Serum Hcy level was found to be significantly higher in patients with AS than in healthy control subjects and addition of folic acid to their therapy may decrease the risk of cardiovascular disease which in turn decreases the mortality in these patients, but further prospective studies are needed for supporting these results. Expand
The relationship between plasma homocysteine level and different treatment modalities in patients with ankylosing spondylitis
TLDR
Plasma homocysteine levels in ankylosing spondylitis patients were statistically significantly lower compared with those in the healthy control group and there was no significant difference among sub-groups established on the basis of medical treatments and disease activity (BASDAI ≤4 and >4). Expand
Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis
TLDR
A meta-analysis indicates that HCY levels are similar between AS and controls, and do not correlate with disease activity, however, different medical treatments cause fluctuations of circulating HCy levels in AS patients. Expand
Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables
TLDR
A significant prevalence of hyperhomocysteinemia is found in Mexican patients with AS mainly associated to a worst functional impairment and further follow-up studies are required to evaluate the risk of cardiovascular disease in these patients. Expand
Atherosclerosis in male patients with ankylosing spondylitis: the relation with methylenetetrahydrofolate reductase (C677T) gene polymorphism and plasma homocysteine levels
TLDR
An association between MTHFR 677 gene polymorphism and pHcy levels was concluded, which may suggest that MTHfr 677 TT polymorphism may be a potential prognostic factor for cardiovascular disease in patients with Ankylosing spondylitis. Expand
Elevated Serum Level of IL-33 and sST2 in Patients With Ankylosing Spondylitis
Objective Interleukin (IL)-33 is a cytokine belonging to the IL-1 family and was recently identified as a ligand for ST2, which belongs to the IL-1 receptor (IL-1R) family. In this study, we aimed toExpand
Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases?
TLDR
The attention is focused on the relationship between homocysteine (Hcy) and CVD in patients affected with autoimmune diseases, reviewing the most recent literature data and also providing the original experience. Expand
Serum levels of IL-33 is increased in patients with ankylosing spondylitis
TLDR
IL-33 may play a role in ankylosing spondylitis development via enhancing TNF-α production by PBMCs and inducing neutrophil migration and IL-33 concentrations in serum were elevated in AS patients. Expand
Ankylosing Spondylitis: Chinese Perspective, Clinical Phenotypes, and Associated Extra-articular Systemic Features
TLDR
Of extra-articular manifestations, AS patients have earlier onset and more recurrent attacks of HLA-B27-related acute anterior uveitis and apical lung diseases in Chinese AS patients are also frequently associated with tuberculosis infection. Expand
Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis.
TLDR
Common educational programs for specialists and general practitioners and appropriate CV prevention programs, taking into consideration traditional VRFs as well as the inflammatory status, should be planned to prevent ischemic events and to achieve optimal inflammation control in rheumatic patients. Expand
...
1
2
...

References

SHOWING 1-10 OF 12 REFERENCES
Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation.
TLDR
Men with AS have perturbances in several CHD risk factors, which appear to be driven principally by systemic inflammatory mediators. Expand
Hyperhomocysteinemia: an independent risk factor for vascular disease.
TLDR
Hyperhomocysteinemia is an independent risk factor for vascular disease, including coronary disease, and in most instances is probably due to cystathionine beta-synthase deficiency. Expand
Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis.
TLDR
The results support previous findings of folate deficiency and haemolysis occurring in a considerable fraction of patients receiving treatment with SASP and suggest that a substantial number of patients may have folATE deficiency at the tissue level. Expand
Homocysteine and thrombotic disease.
TLDR
Two different forms of the disease can be primarily as a universal methyl donor to a variety of acdistinguished on the basis of the responsiveness to treatment ceptors including guanidinoacetate, nucleic acids, neurowith large dosages of vitamin B6. Expand
The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease.
TLDR
Elevated plasma homocyst(e)ine is an independent risk factor for symptomatic lower extremity disease or cerebral vascular disease or both and appears to have more rapid progression of disease. Expand
Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.
TLDR
It is concluded that this condition predisposes to the development of premature occlusive arterial disease, causing intermittent claudication, renovascular hypertension, and ischemic cerebrovascular disease. Expand
Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement.
TLDR
The results indicate low dose folic acid supplementation has a beneficial effect on MTX toxicity, and the intracellular concentration of MTX may play a role. Expand
Moderate Homocysteinemia - A Possible Risk Factor For Arteriosclerotic Cerebrovascular Disease
TLDR
The present study demonstrates a significantly elevated mean plasma MDS concentration in 19 patients with arteriosclerotic cerebrovascular disease compared to 17 controls, and suggests that moderate homocysteinemia might be a risk factor for arteriosclerosis. Expand
Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease.
TLDR
The highest levels of homocysteine were present in patients with coronary disease and another symptomatic localisation of atherosclerosis, and the presence of both hypertension and hyperhomocysteinemia was associated with more severe coronary Atherosclerosis. Expand
Homocysteine modification of HLA antigens and its immunological consequences
TLDR
The results are discussed in relation to the potential involvement of homocysteine‐specific CTL in ankylosing spondylitis and reactive arthritis, both of which are related to bacterial infections, associated with HLA B27, and considered to be autoimmune diseases. Expand
...
1
2
...